We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Agilent Acquires Its Analytic Joint Venture

By Biotechdaily staff writers
Posted on 16 Feb 2006
Agilent Technologies Inc. More...
(Palo Alto, CA, USA), and Yokogawa Electric Corp. (Tokyo, Japan) have announced that their joint venture, Yokogawa Analytical Systems, became a wholly owned Agilent subsidiary on February 1, 2006.

Yokogawa Analytical Systems was founded as a joint venture by Agilent and Yokogawa Electric in 1992. The company designed and produced measurement and control and industrial automation systems, including inductively coupled plasma mass spectrometry (ICP/MS) systems, which are analytic systems used in gas chromatography for laboratory and other scientific applications. Agilent and Yokogawa noted that the joint venture achieved its original objectives.

Agilent decided that it is the right time for Yokogawa Analytical Systems to become a wholly owned subsidiary in order to expand the market presence for its products and services in Japan. By selling its stake in the joint venture, Yokogawa Electric will be able to dedicate additional resources to its core businesses. The firm is receiving approximately U.S.$106 million for the transaction, including $98 million from Agilent for its 49% share in the joint venture, and $7.5 million in dividends from Yokogawa Analytical Systems.

Yokogawa Electric was founded in 1915 and is engaged in research and innovation. Its core businesses are industrial automation and control, test and measurement, information systems, and industry support.

"Yokogawa and Agilent have had a very strong, cooperative relationship over the past 13 years,” said Ryuji Kanno, president, Yokogawa Analytical Systems. "This acquisition of Yokogawa's minority share is a positive step for both companies.”



Related Links:
Agilent
Yokogawa

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Repetitive Pipette
VWR® Stepper Pro
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.